Xeomin (incobotulinumtoxinA) has been approved by the U.S. Food and Drug Administration for the treatment of chronic sialorrhea, or excessive drooling, a common condition in amyotrophic lateral sclerosis (ALS) patients. Merz Neurosciences, a division of Merz North America, recently announced that its supplemental biologics license application (sBLA) for Xeomin was…
Search results for:
Rare gene mutations in amyotrophic lateral sclerosis (ALS) will be increasingly identified with large-scale, international studies, findings from Project MinE suggest. The study, “Project MinE: study design and pilot analyses of a large-scale whole-genome sequencing study in amyotrophic lateral sclerosis,” was published in the European…
NurOwn, an amyotrophic lateral sclerosis (ALS) treatment candidate, will not be made available under the new Right to Try Act at this time due to a lack of funding alternatives for patients, BrainStorm Cell Therapeutics announced in a press release. The company said it reached this decision after carefully evaluating the Right to…
Flex Pharma announced that it is stopping Phase 2 clinical trials of its investigational compound to ease muscle cramps, FLX-787, in patients with amyotrophic lateral sclerosis (ALS) and Charcot-Marie-Tooth disease (CMT). The company’s decision was based on tolerability concerns in each study with the oral disintegrating tablet formulation at 30…
News
Insights from New System May Help Improve Speech Impairment in ALS, Other Disorders, Study Reports
A new portable system provides insights into the altered tongue, lip, and jaw motion in amyotrohic lateral sclerosis (ALS) patients with a speech disorder called dysarthria. The instrument could be valuable for both diagnosis and treatment of speech impairment. The study, “Articulatory Range of Movement…
News
Two Enzymes Play Key Role Against Stress Granules in ALS, Other Neurological Disorders, Study Finds
Two enzymes called USP5 and USP13 were found to have an important role in fighting back against toxic “stress granules,” a study reports. The study, titled “Deubiquitylases USP5 and USP13 are recruited to and regulate heat-induced stress granules through their deubiquitylating activities,” and published in the …
AB Science has decided not to seek the re-examination it initially requested after the European Medicines Agency (EMA) issued a negative opinion on marketing authorization for masitinib, the company’s investigational amyotrophic lateral sclerosis (ALS) therapy. The company announced in a press release that the re-examination procedure…
The Muscular Dsytrophy Association (MDA) awarded 13 new grants totaling $2.6 million to find treatments for neuromuscular disorders, including amyotrophic lateral sclerosis (ALS). The 13 grants are divided into three types: Five grants were awarded to recognized, independent researchers; Five development grants were awarded to early-career scholars, and;…
Mutations in the C9orf72 gene deregulate the process by which cells remove waste, leading to a buildup of toxic elements inside them, researchers have found. This discovery expands knowledge on how C9orf72 may contribute to the development and progression of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS)…
NurOwn, a cell therapy being developed by Brainstorm Cell Therapeutics, is able to maintain its therapeutic effects by significantly regulating the levels of a type of small RNA molecule linked to amyotrophic lateral sclerosis (ALS), a study suggests. According to data from a Phase 2 trial, the investigative therapy can…